BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer. 2006;94:287-292. [PMID: 16404431 DOI: 10.1038/sj.bjc.6602923] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Ward DG, Nyangoma S, Joy H, Hamilton E, Wei W, Tselepis C, Steven N, Wakelam MJ, Johnson PJ, Ismail T. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 2008;6:19. [PMID: 18558005 DOI: 10.1186/1477-5956-6-19] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
2 Vanhooren V, Dewaele S, Libert C, Engelborghs S, De Deyn PP, Toussaint O, Debacq-chainiaux F, Poulain M, Glupczynski Y, Franceschi C, Jaspers K, van der Pluijm I, Hoeijmakers J, Chen CC. Serum N-glycan profile shift during human ageing. Experimental Gerontology 2010;45:738-43. [DOI: 10.1016/j.exger.2010.08.009] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 6.8] [Reference Citation Analysis]
3 Pakharukova NA, Pastushkova LK, Popova YA, Trifonova OP, Larina IM. Study of Normal Human Serum Proteomic Profile under Conditions of Hyperbaric Oxygen-Nitrogen-Argon Exposure. Bull Exp Biol Med 2010;149:37-9. [DOI: 10.1007/s10517-010-0869-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer. 2009;9:287. [PMID: 19689818 DOI: 10.1186/1471-2407-9-287] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
5 Shi L, Zhang J, Wu P, Feng K, Li J, Xie Z, Xue P, Cai T, Cui Z, Chen X, Hou J, Zhang J, Yang F. Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci 2009;7:7. [PMID: 19291297 DOI: 10.1186/1477-5956-7-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
6 Hodgetts A, Levin M, Kroll JS, Langford PR. Biomarker discovery in infectious diseases using SELDI. Future Microbiology 2007;2:35-49. [DOI: 10.2217/17460913.2.1.35] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
7 Chen N, Sun W, Deng X, Hao Y, Chen X, Xing B, Jia W, Ma J, Wei H, Zhu Y, Qian X, Jiang Y, He F. Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics 2008;8:5108-18. [DOI: 10.1002/pmic.200800280] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
8 Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol. 2010;17:2518-2525. [PMID: 20354800 DOI: 10.1245/s10434-010-1038-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
9 Yan HJ, Chen ZJ, Zeng Q, Chen C, Zhang LH, Li N, Xu Y. Screening serum biomarkers of fatty liver disease using proteomic technology. Shijie Huaren Xiaohua Zazhi 2008; 16(34): 3904-3909 [DOI: 10.11569/wcjd.v16.i34.3904] [Reference Citation Analysis]
10 Göbel T, Vorderwülbecke S, Hauck K, Fey H, Häussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006; 12(47): 7604-7612 [PMID: 17171788 DOI: 10.3748/wjg.v12.i47.7604] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
11 Hu YB, Lin HL, Hao MZ, Ye YB, Chen HJ, Chen QZ, Chen Q. Application of surface-enhanced laser desorption ionization time-of-flight mass spectrometry to the diagnosis and evaluation of interventional effect in patients with hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2012; 20(13): 1107-1111 [DOI: 10.11569/wcjd.v20.i13.1107] [Reference Citation Analysis]
12 Cao XL, Li H, Yu XL, Liang P, Dong BW, Fan J, Li M, Liu FY. Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature. PLoS One 2013;8:e82448. [PMID: 24349287 DOI: 10.1371/journal.pone.0082448] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Gui HL, Gao CF, Wang H, Liu XE, Xie Q, Dewaele S, Wang L, Zhuang H, Contreras R, Libert C. Altered serum N-glycomics in chronic hepatitis B patients. Liver Int. 2010;30:259-267. [PMID: 19951379 DOI: 10.1111/j.1478-3231.2009.02170.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
14 Rathinam S, Alzetani A, Starczynski J, Rajesh PB, Nyangoma S, Wakelam MJO, James ND, Wei W, Billingham LJ, Johnson PJ, Martin A, Ward DG. Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery. Clin Proteom 2009;5:148-55. [DOI: 10.1007/s12014-009-9033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Lin Y, Dynan WS, Lee JR, Zhu ZH, Schade RR. The current state of proteomics in GI oncology. Dig Dis Sci 2009;54:431-57. [PMID: 19104933 DOI: 10.1007/s10620-008-0656-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
16 Albrethsen J, Bøgebo R, Møller CH, Olsen JA, Raskov HH, Gammeltoft S. Candidate biomarker verification: Critical examination of a serum protein pattern for human colorectal cancer. Proteomics Clin Appl. 2012;6:182-189. [PMID: 22532454 DOI: 10.1002/prca.201100095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
17 Espejel F, Carlos Roa J. Surface enhanced laser desorption/ionization (SELDI): tecnología proteómica y su aplicación en oncología. Medicina Clínica 2008;131:312-7. [DOI: 10.1016/s0025-7753(08)72265-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Yang GH, Dai Z, Zhou J. Advance in proteomic study of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2008; 16(22): 2487-2492 [DOI: 10.11569/wcjd.v16.i22.2487] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Cho WC. [Research progress in SELDI-TOF MS and its clinical applications]. Sheng Wu Gong Cheng Xue Bao 2006;22:871-6. [PMID: 17168305 DOI: 10.1016/s1872-2075(06)60061-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
20 Paik YK, Kim H, Lee EY, Kwon MS, Cho SY. Overview and introduction to clinical proteomics. Methods Mol Biol 2008;428:1-31. [PMID: 18287765 DOI: 10.1007/978-1-59745-117-8_1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
21 Liao J, Yin ZF. Progress in proteomics-based diagnosis of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(3): 284-287 [DOI: 10.11569/wcjd.v17.i3.284] [Reference Citation Analysis]
22 Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology. 2008;51 Suppl 1:34-41. [PMID: 18544946 DOI: 10.1159/000122596] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
23 Ressom HW, Varghese RS, Goldman L, An Y, Loffredo CA, Abdel-Hamid M, Kyselova Z, Mechref Y, Novotny M, Drake SK, Goldman R. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res 2008;7:603-10. [PMID: 18189345 DOI: 10.1021/pr0705237] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
24 Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010;8:70. [PMID: 21192835 DOI: 10.1186/1477-5956-8-70] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
25 Teng M, Pirrie S, Ward DG, Assi LK, Hughes RG, Stocken D, Johnson PJ. Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. Br J Cancer. 2014;110:2277-2282. [PMID: 24603305 DOI: 10.1038/bjc.2014.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Li Y, Wu J, Zhang W, Zhang N, Guo H. Identification of serum CCL15 in hepatocellular carcinoma. Br J Cancer. 2013;108:99-106. [PMID: 23321514 DOI: 10.1038/bjc.2012.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
27 Piyathilake CJ, Oelschlager DK, Meleth S, Partridge EE, Grizzle WE. Plasma Protein Profiles Differ between Women Diagnosed with Cervical Intraepithelial Neoplasia (CIN) 1 and 3. Cancer Inform 2006;2:117693510600200. [DOI: 10.1177/117693510600200026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Prattichizzo C, Gigante M, Pontrelli P, Stella A, Rocchetti MT, Gigante M, Maiorano E, Herr W, Battaglia M, Gesualdo L, Ranieri E. Establishment and characterization of a highly immunogenic human renal carcinoma cell line. Int J Oncol 2016;49:457-70. [PMID: 27278998 DOI: 10.3892/ijo.2016.3544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer. 2006;94:1898-1905. [PMID: 16755300 DOI: 10.1038/sj.bjc.6603188] [Cited by in Crossref: 155] [Cited by in F6Publishing: 146] [Article Influence: 9.7] [Reference Citation Analysis]
30 Forshed J, Pernemalm M, Tan CS, Lindberg M, Kanter L, Pawitan Y, Lewensohn R, Stenke L, Lehtiö J. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia. J Proteome Res 2008;7:2332-41. [PMID: 18452325 DOI: 10.1021/pr070482e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
31 Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Martin A, Beaugrand M, Johnson PJ. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer. 2006;95:1379-1383. [PMID: 17060939 DOI: 10.1038/sj.bjc.6603429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
32 Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev 2007;31:35-44. [PMID: 17293059 DOI: 10.1016/j.cdp.2006.11.003] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
33 Lancashire LJ, Lemetre C, Ball GR. An introduction to artificial neural networks in bioinformatics--application to complex microarray and mass spectrometry datasets in cancer studies. Brief Bioinform. 2009;10:315-329. [PMID: 19307287 DOI: 10.1093/bib/bbp012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 63] [Article Influence: 7.2] [Reference Citation Analysis]
34 Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 2007;6:25. [PMID: 17407558 DOI: 10.1186/1476-4598-6-25] [Cited by in Crossref: 156] [Cited by in F6Publishing: 144] [Article Influence: 10.4] [Reference Citation Analysis]
35 Liu L, Liu J, Wang Y, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D. A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers 2010;16:20-30. [DOI: 10.3109/1354750x.2010.521257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
36 He M, Qin J, Zhai R, Wei X, Wang Q, Rong M, Jiang Z, Huang Y, Zhang Z. Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach. Proteome Sci 2008;6:10. [PMID: 18331625 DOI: 10.1186/1477-5956-6-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
37 Cui JF, Liu YK, Zhou HJ, Kang XN, Huang C, He YF, Tang ZY, Uemura T. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J Gastroenterol 2008; 14(8): 1257-1262 [PMID: 18300354 DOI: 10.3748/wjg.14.1257] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
38 Tammen H, Peck A, Budde P, Zucht H. Peptidomics analysis of human blood specimens for biomarker discovery. Expert Review of Molecular Diagnostics 2014;7:605-13. [DOI: 10.1586/14737159.7.5.605] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
39 Mas VR, Fisher RA, Archer KJ, Maluf DG. Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics. 2009;6:421-431. [PMID: 19681677 DOI: 10.1586/epr.09.59] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
40 Molina S, Missé D, Roche S, Badiou S, Cristol J, Bonfils C, Dierick J, Veas F, Levayer T, Bonnefont-rousselot D, Maurel P, Coste J, Fournier-wirth C. Identification of apolipoprotein C-III as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection. Prot Clin Appl 2008;2:751-61. [DOI: 10.1002/prca.200800020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
41 Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46:1426-1435. [PMID: 17683101 DOI: 10.1002/hep.21855] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 8.0] [Reference Citation Analysis]
42 Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D. Reduced transthyretin expression in sera of lung cancer. Cancer Science 2007;98:1617-24. [DOI: 10.1111/j.1349-7006.2007.00576.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
43 Ward DG, Wei W, Buckels J, Taha AM, Hegab B, Tariciotti L, Salih R, Qi YQ, Martin A, Johnson PJ. Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen. Eur J Gastroenterol Hepatol 2010;22:1358-63. [PMID: 20555269 DOI: 10.1097/MEG.0b013e32833b6d41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
45 Pakharukova NA, Pastushkova LK, Trifonova OP, Moshkovskii SA, Larina IM. Variability of low-molecular-weight serum subproteome in healthy humans under the conditions of normal vital activity. Hum Physiol 2011;37:193-9. [DOI: 10.1134/s0362119711020149] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]